Correlation between pill counts and biologic effects in an HIV-1 prevention clinical trial: Implications for measuring adherence

AIDS and Behavior

Volumn 17, Issue 2, 2013, Pages 632-639

  Donnell, Deborah J ^a,b   Baeten, Jared M ^a   Hong, Ting ^a   Lingappa, Jairam R ^a,c   Mujugira, Andrew ^a   Nakku Joloba, Edith ^a   Bangsberg, David ^d,e   Celum, Connie ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

HIV prevention; Medication adherence; Pill count

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; VIRUS RNA;

ADULT; AFRICA; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MONITORING; EQUIPMENT; FAMILY SIZE; FEMALE; GENITAL HERPES; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; STATISTICS; VIRUS LOAD;

ACYCLOVIR; ADULT; AFRICA; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; DRUG MONITORING; FAMILY CHARACTERISTICS; FEMALE; HERPES GENITALIS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MEDICATION ADHERENCE; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; VIRAL LOAD;

MLCS; MLOWN;

EID: 84880917938     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-012-0268-0     Document Type: Article

References (30)

1. Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S79-87.
2. Kerr T, Walsh J, Lloyd-Smith E, Wood E. Measuring adherence to highly active antiretroviral therapy: implications for research and practice. Curr HIV/AIDS Rep. 2005;2(4):200-5.
3. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134(10):968-77.
4. Rudd P, Byyny RL, Zachary V, et al. The natural history of medication compliance in a drug trial: limitations of pill counts. Clin Pharmacol Ther. 1989;46(2):169-76.
5. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168-74.
6. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-99.
7. Garvie PA, Wilkins ML, Kolivas ED, Young JC. Multimethod adherence assessment in children with perinatally acquired HIV-1: the influence of off-schedule dosing in predicting biological markers. Pediatr Infect Dis J. 2010;29(4):372-4.
8. Hansen RA, Kim MM, Song L, Tu W, Wu J, Murray MD. Comparison of methods to assess medication adherence and classify nonadherence. Ann Pharmacother. 2009;43(3):413-22.
9. Wagner GJ. Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries. AIDS Patient Care STDs. 2002;16(12):599-608.
10. Pullar T, Kumar S, Tindall H, Feely M. Time to stop counting the tablets? Clin Pharmacol Ther. 1989;46(2):163-8.
11. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9):1181-3.
12. Lingappa JR, Kahle E, Mugo N, et al. Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One. 2009;4(4):e5272.
13. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med. 2010;362(5):427-39.
14. Baeten JM, Strick LB, Lucchetti A, et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis. 2008;198(12):1804-8.
15. Delany S, Mlaba N, Clayton T, et al. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS. 2009;23(4):461-9.
16. Fuchs J, Celum C, Wang J, et al. Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trial. J Infect Dis. 2010;201(8):1164-8.
17. Nagot N, Ouedraogo A, Foulongne V, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med. 2007;356(8):790-9.
18. Paz-Bailey G, Sternberg M, Puren AJ, et al. Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: a randomized, controlled trial. J Infect Dis. 2009;200(7):1039-49.
19. Zuckerman RA, Lucchetti A, Whittington WL, et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis. 2007;196(10):1500-8.
20. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375(9731):2092-8.
21. Jerome KR, Huang ML, Wald A, Selke S, Corey L. Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR. J Clin Microbiol. 2002;40(7):2609-11.
22. Wald A, Huang ML, Carrell D, Selke S, Corey L. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis. 2003;188(9):1345-51.
23. Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371(9630):2109-19.
24. Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med. 2008;358(15):1560-71.
25. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14(4):357-66.
26. Kalichman SC, Amaral C, Swetsze C, et al. Monthly unannounced pill counts for monitoring HIV treatment adherence: tests for self-monitoring and reactivity effects. HIV Clin Trials. 2010;11(6):325-31.
27. Van Damme L, Corneli A, Ahmed K, et al. The FEM-PrEP trial of emtricitabine/tenofovir disoproxil fumarate (Truvada) among African women. In: 19th Conference on retroviruses and opportunistic infections, 5-8 March, Seattle, 2012 [abstract LB-32].
28. Baeten J, Donnell D, Ndase P, Mugo N, Mujugira A, Celum C. ARV PrEP for HIV-1 prevention among heterosexual men and women. In: 19th Conference on retroviruses and opportunistic infections, 5-8 March, Seattle, 2012 [abstract 29].
29. Reitano M, Tyring S, Lang W, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group. J Infect Dis. 1998;178(3):603-10.
30. Goldberg LH, Kaufman R, Kurtz TO, et al. Long-term suppression of recurrent genital herpes with acyclovir. A 5-year benchmark. Acyclovir Study Group. Arch Dermatol. 1993;129(5):582-7.